An exciting study published in Nature Communications on October 4, 2023, authored by Zhao, L., Koseki, S.R.T., Silverstein, R.A., et al., delves into overcoming limitations in CRISPR genome editing by introducing SpRYc—a chimeric Cas9 resulting from the fusion of Sc++ and SpRY. Unlike conventional Cas9 enzymes, SpRYc breaks free from the constraints of specific protospacer adjacent motifs (PAMs) by accommodating a 5’-NNN-3’ PAM preference. The chimeric SpRYc, engineered through a strategic grafting of SpRY’s PAM-interacting domain onto Sc++, showcases remarkable PAM flexibility, allowing specific editing of diverse 5’-NNN-3’ PAM targets in human cells.
In the development of SpRYc, substantial substitutions in the PAM-interacting domain (PID) of SpCas9 endowed it with a more flexible 5’-NRN-3’ PAM specificity. In contrast, ScCas9 and Sc + + leverage positive-charged, flexible loop structures in their N-termini, favoring a minimal 5’-NNG-3’ PAM preference. Building upon previous successes like iSpyMac, SpRYc emerged from the intelligent exchange of the PID of Sc + + with that of SpRY, creating a chimeric hybrid Cas9.
PAM characterization of SpRYc, utilizing the PAM-SCANR assay and HT-PAMDA, demonstrated its robust binding to PAM sequences, suggesting potential optimization as a “dead” or nickase variant. Despite slower cleavage rates than SpRY, SpRYc showcased broader editing capabilities, paving the way for its application in both nuclease and non-cleavage editing formats.
In silico modeling of SpRYc, conducted via the SWISS-MODEL server, revealed insights into its PAM targeting mechanisms. The study suggested that Sc + +’s optimized loop establishes nonspecific interactions with the PAM, broadening targeting and reducing the need for specific bases at position 2. Importantly, SpRYc’s interactions did not induce self-editing of gRNA plasmids, addressing concerns associated with PAM-flexible CRISPR enzymes.
The discussion emphasizes the significance of overcoming PAM limitations in CRISPR-Cas9 genome editing. SpRYc, with its flexible PAM preferences, exhibits robust editing capabilities, making it suitable for non-nuclease applications like base editing and CRISPR-mediated regulation. The potential integration of high-fidelity mutations into SpRYc further highlights its promise for improved specificity. The study underscores the role of advanced in silico and in vitro PAM engineering methods, emphasizing the synergy of computational algorithms, directed evolution, and structural modeling in protein design. SpRYc marks a significant step toward the future of integrative protein engineering approaches in genome editing.
Zhao, L., Koseki, S.R.T., Silverstein, R.A. et al. PAM-flexible genome editing with an engineered chimeric Cas9. Nat Commun 14, 6175 (2023). https://doi.org/10.1038/s41467-023-41829-y
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.